AstraZeneca PLC’s Recentin Flunks Colon Cancer Tests

LONDON, May 28 (Reuters) - AstraZeneca (AZN.L) dropped plans to file experimental cancer drug Recentin as a first-line treatment for colon cancer on Friday after disappointing results from a second pivotal clinical trial with the medicine.